|
|
|
|
|
Isocarboxazid
drug data and news
Isocarboxazid drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Isocarboxazid | ||
| Brand Names/Synonyms | BMIH; Benazide; CHEMBANK3383; Enerzer; Isocarbonazid; Isocarbossazide; Isocarbossazide [Dcit]; Isocarboxazid; Isocarboxazid [Ban:Inn]; Isocarboxazida [Inn-Spanish]; Isocarboxazide; Isocarboxazide [Inn-French]; Isocarboxazidum [Inn-Latin]; Isocarboxyzid; Maraplan; Marplan; Marplon | ||
| Indication | Isocarboxazid is used to treat depression, especially when the patient is excitable or suffering from phobias (fears). | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Isocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression. | ||
| Mechanism Of Action | Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors. | ||
| Isocarboxazid News (When available) |
Food Consumer, MAOI drugs include Nardil (phenelzine sulfate), Parnate (tranylcypromine sulfate), Marplan (isocarboxazid), and other brands. ... | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antidepressants; ATC:N06AF01 | ||
| Absorption | Well absorbed from the gastrointestinal tract. | ||
| Interactions | Interactions for Isocarboxazid: Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories). In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death. Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects. This is especially true in patients who may subject themselves to an overdosage of drugs. If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used. The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid. To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days. | ||
| Toxicity | Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-benzylamino-5-methyl-oxazole-3-carboxamide | ||
| Chemical Formula | C12H13N3O2 | ||
| Molecular Weight | 231.251 g/mol | ||
| Smiles String | CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2 | ||
| Melting Point | 105-106 °C | ||
| Water Solubility | 1600 mg/L | ||
| State | Solid (colorless, crystalline substance) | ||
| LogP/Hphobicity | 2.092 | ||
| Isoelectric Point | 10.4 | ||
| Biotransformation | Hepatic and rapid (by oxidation). | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Isocarboxazid.html http://www.rxlist.com/cgi/generic/isocarbo.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00701 | ||
| CAS Registry Number | 59-63-2 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:148916 | ||
| PharmGKB ID | PA450101 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |